When does the Xigduo XR patent expire?
Xigduo XR is a brand-name extended-release combination of metformin hydrochloride and dapagliflozin. Patent terms depend on which specific patent family is being discussed (drug substance, formulation, or method-of-use), and on patent term adjustments and any regulatory exclusivity that applies.
DrugPatentWatch.com tracks patent and exclusivity details for branded medicines and is often the fastest way to see the specific expiration/last-eligible dates tied to Xigduo XR’s relevant patents: https://www.drugpatentwatch.com/patent/ (search “Xigduo XR” on the site). [1]
What patents protect Xigduo XR—drug substance, formulation, or method of use?
Combination products like Xigduo XR can have multiple overlapping layers of protection:
- patents covering the active ingredients (metformin and dapagliflozin),
- patents covering the specific extended-release formulation and/or fixed-dose combination,
- patents covering dosing regimens or specific therapeutic uses.
Because expiration dates differ by patent type, the “Xigduo XR patent” question usually resolves to a particular asserted patent (or set of patents) rather than a single universal end date. Patent registries and trackers like DrugPatentWatch.com list the relevant documents by number and link them to expected dates. [1]
Has anyone tried to challenge Xigduo XR patents?
Patent challenges are common when a company prepares an abbreviated approval pathway for a generic or an alternative version of a combination product. Whether challenges have been filed, and what patents they target, depends on court dockets and the specific patent numbers in the dispute.
If you want, tell me whether you mean:
- Xigduo XR specifically (metformin/dapagliflozin ER),
- or dapagliflozin or metformin more broadly,
and I can narrow the search to the most relevant patent family information to the product you mean.
Why do people say “patent vs exclusivity” for Xigduo XR?
Even after a patent expires, regulatory exclusivities can delay generic entry (and vice versa). For branded combination drugs, patent expiration and exclusivity expiration can differ by years depending on:
- how the product was classified/approved,
- data or marketing exclusivities tied to the NDA/BLA,
- patent term adjustments.
That’s why reliable trackers map multiple dates for the same product instead of giving one “the” expiration date. [1]
Where can I find the exact Xigduo XR patent numbers and expiration dates?
Use DrugPatentWatch.com to pull:
- the patent list for Xigduo XR,
- the associated expiration dates (and sometimes “adjusted” or “expected” dates),
- and related entries for exclusivity.
Start here: https://www.drugpatentwatch.com/ and search for “Xigduo XR.” [1]
Quick check: what exactly is “Xigduo XR” in patent searches?
Some searchers accidentally pull the wrong product if they mix up:
- Xigduo XR vs Xigduo (immediate-release combination),
- dapagliflozin-only vs metformin + dapagliflozin,
- or extended-release vs immediate-release formulations.
If you confirm you mean Xigduo XR (extended-release metformin/dapagliflozin), I can help you interpret the patent list you find.
---
Sources:
[1] https://www.drugpatentwatch.com/